Active drugs for the treatment of advanced melanoma are now available, including combinations of BRAF plus MEK inhibitors for BRAF-mutant melanoma and immune-checkpoint blockers for all melanomas regardless of BRAF status, especially regimens based on PD-1.¹ What works in the advanced setting is also effective in the adjuvant setting, especially the combination of dabrafenib and trametinib in patients with stage III BRAF-mutant melanoma² and nivolumab for all melanoma types in patients with stage IIIB or IIIC–IV disease.

中文翻译：

---

黑色素瘤的新辅助治疗：下一步？

现在已有用于治疗晚期黑色素瘤的活性药物，包括BRAF加MEK抑制剂（针对BRAF突变性黑色素瘤）和针对所有黑色素瘤的免疫检查点阻滞剂，而不论BRAF的状态如何，尤其是基于PD-1的方案。¹在晚期治疗中有效的方法在辅助治疗中也有效，特别是对于IIIB期或IIIC-IV期疾病的所有类型的BRAF突变型黑色素瘤²和nivolumab的III期BRAF突变型患者，dabrafenib和trametinib的联合使用均有效。